Search results
Why Big Pharma Is Following Novartis' Lead In A $25 Billion Market
Investor's Business Daily· 13 hours agoActinium is working on a radiopharmaceutical-based treatment foracute myeloid leukemia. But more...
HanxBio announces the publication of a research paper in Scientific Reports on preclinical...
FOX 4 Kansas City· 3 days agoHanxBio today announced that it has published a research article titled "Narazaciclib, a novel...
FDA grants breakthrough status for Kura Oncology's AML drug candicate By Investing.com
Investing.com· 4 days agoFood and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to its drug...
Deverra Therapeutics Granted FDA Fast Track Designation for DVX101
Digital Journal· 1 day agoDesignation Validates Preliminary Data and Supports Accelerated Drug Development SEATTLE, WA / ACCESSWIRE / April 24, 2024 / Deverra Therapeutics, Inc., a clinical-stage biotechnology company ...
Study reveals insights into DDX41 protein's role in blood cancer pathogenesis
Medical Xpress· 2 days agoA study led by Professors Hongtae Kim and JaYil Lee from the Department of Biological Sciences, in collaboration with researchers from the Catholic University of Korea, sheds light on the pivotal ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 14 hours agoSAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will
Secondary cancer: Why breast cancer survivors have a higher risk
Medical News Today· 18 hours agoThe age of cancer diagnosis appears to affect second cancer risk, especially for women, as does economic status. In it, researchers from the University of Cambridge in England report that women ...
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest...
Morningstar· 1 day agoSUZHOU, China and ROCKVILLE, Md., April 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 4 days agoFood and Drug Administration (FDA) for the treatment of patients with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML ...
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases
BioPharma Dive via Yahoo Finance· 4 days agoIpsen, for instance, formed a partnership with Accent Therapeutics in 2021 develop a drug for acute ...
